Cargando…

Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo

The development of targeted therapies (BRAF/MEK inhibitors) and immunotherapy have had a major impact on the treatment of melanoma. However, the majority of patients with advanced melanomas succumb to their disease. The mechanisms of resistance to both targeted therapies and immunotherapies are nume...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radi, Rakan, Huang, Christina, Elsey, Justin, Jung, Yoon H., Corces, Victor G., Arbiser, Jack L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137681/ https://www.ncbi.nlm.nih.gov/pubmed/35624662 http://dx.doi.org/10.3390/antiox11050798

Ejemplares similares

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)

Mitochondrial Metabolism in Melanoma
por: Huang, Christina, et al.
Publicado: (2021)

Introduction of Mutant GNAQ into Endothelial Cells Induces a Vascular Malformation Phenotype with Therapeutic Response to Imatinib
por: Sasaki, Maiko, et al.
Publicado: (2022)

Hyperconjugative aromaticity and protodeauration reactivity of polyaurated indoliums
por: Xiao, Kui, et al.
Publicado: (2019)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Three-Component Reactions of 3-Arylidene-3H-Indolium Salts, Isocyanides and Amines
por: Nguyen, Hung M., et al.
Publicado: (2021)

Synthesis of tetra- and octa-aurated heteroaryl complexes towards probing aromatic indoliums
por: Yuan, Jun, et al.
Publicado: (2016)

Benz[c,d]indolium-containing Monomethine Cyanine Dyes: Synthesis and Photophysical Properties
por: Soriano, Eduardo, et al.
Publicado: (2015)

Three-Component Reaction of 3-Arylidene-3H-Indolium Salts, Isocyanides, and Alcohols
por: Golantsov, Nikita E., et al.
Publicado: (2019)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

Palladium based nanoparticles for the treatment of advanced melanoma
por: Elsey, Justin, et al.
Publicado: (2019)

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019)

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
por: Salton, Maayan, et al.
Publicado: (2015)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
por: Zhao, Kun, et al.
Publicado: (2020)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells
por: Tabolacci, Claudio, et al.
Publicado: (2022)

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
por: Vital, Patrik da Silva, et al.
Publicado: (2022)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma
por: Signetti, Laurie, et al.
Publicado: (2020)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance
por: Radić, Martina, et al.
Publicado: (2022)

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
por: Kemper, Kristel, et al.
Publicado: (2015)

Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation
por: Foda, Bardees M., et al.
Publicado: (2023)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019)

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
por: Dratkiewicz, Ewelina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_em5g5aees4pp4huaolonp16lqa